共同设计一个移动应用程序,以提高心脏动患者的药物坚持
Alice Pearsons1, Coral L Hanson1,2, Janet Hanley1
1Edinburgh Napier University, School of Health and Social Care, Sighthill Campus, Sighthill Court, Edinburgh, EH11 4BN, Scotland.
European journal of cardiovascular nursing
|January 14, 2026
概括
与心房患者共同设计移动应用程序改善了药物坚持工具. MyAFNurse应用程序为患者提供了跟踪和信息,以解决更好的自我护理的现实需求.
科学领域:
- 数字健康数字健康
- 行为科学 行为科学
- 心脏病学 心脏病学
背景情况:
- 口服抗凝药对于预防心房动 (AF) 中的中风至关重要.
- 药物不服药影响高达30%的AF患者,增加中风风险.
- 移动健康 (mHealth) 应用程序可以通过行为改变技术来提高药物坚持.
研究的目的:
- 共同设计一个移动健康应用程序,旨在改善心房的患者口服抗凝剂的坚持.
- 让AF患者作为开发过程中的积极参与者参与进来.
主要方法:
- 采用了以个人为基础的方法,以莱文塔尔的常识自我调节模型为指导.
- 进行了三次研讨会:患者讲述故事,对现有mHealth应用程序的审查以及共同设计的应用程序的试点测试.
- 数据收集涉及翻页图,贴纸笔记和研究人员现场笔记,强调直接引用和参与者的经验.
主要成果:
- 涉及11名参与者 (年龄在35-80岁),他们的AF诊断和药物治疗方案各不相同.
- 八名参与者 (72%) 服用口服抗凝剂;只有两人使用智能手机进行健康管理.
- 共同设计的应用程序MyAFNurse包括一个说话的化身,药物跟踪器,AF信息,寻求帮助的建议和知识测试.
结论:
- 共同设计方法通过整合他们的经验和偏好,赋予AF患者权力.
- 这种方法培养了对自我照顾的所有权感.
- 由此产生的mHealth工具MyAFNurse是基于其用户的实际需求.
相关概念视频
01:30Heart Failure V: Medical Management
215
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
215
01:25Dysrhythmias VI: Management of Dysrhythmias
428
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
428
01:21Rheumatic Heart Disease III: Medical Management
282
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
282
01:29Cardiomyopathy V: Interprofessional Care
335
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
335
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.4K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K
01:22Heart Failure VI: Adjunct Therapies
252
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
252